Stemtech Stock Analysis
| STEK Stock | USD 0.0005 0.0001 16.67% |
Stemtech's financial leverage is the degree to which the firm utilizes its fixed-income securities and uses equity to finance projects. Companies with high leverage are usually considered to be at financial risk. Stemtech's financial risk is the risk to Stemtech stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Given that Stemtech's debt-to-equity ratio measures a OTC Stock's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Stemtech is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Stemtech to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Stemtech is said to be less leveraged. If creditors hold a majority of Stemtech's assets, the OTC Stock is said to be highly leveraged.
Stemtech is fairly valued with Real Value of 4.8E-4 and Hype Value of 5.0E-4. The main objective of Stemtech otc analysis is to determine its intrinsic value, which is an estimate of what Stemtech is worth, separate from its market price. There are two main types of Stemtech's stock analysis: fundamental analysis and technical analysis.
The Stemtech otc stock is traded in the USA on OTCQB Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA.
Stemtech |
Stemtech OTC Stock Analysis Notes
About 64.0% of the company outstanding shares are owned by corporate insiders. The company had not issued any dividends in recent years. Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. It offers its dietary supplement products under the RCM System, stemrelease3, Stemflo MigraStem, DermaStem, DermaStem Lift, OraStem, and D-Fuze brands. Stemtech Corp operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.The quote for Stemtech is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. To find out more about Stemtech contact Charles Arnold at 954 715 6000 or learn more at https://www.stemtech.com.Stemtech Investment Alerts
| Stemtech generated a negative expected return over the last 90 days | |
| Stemtech has high historical volatility and very poor performance | |
| Stemtech has some characteristics of a very speculative penny stock | |
| Stemtech currently holds 219.47 K in liabilities. Stemtech has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Stemtech until it has trouble settling it off, either with new capital or with free cash flow. So, Stemtech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Stemtech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Stemtech to invest in growth at high rates of return. When we think about Stemtech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 4.32 M. Net Loss for the year was (7.08 M) with profit before overhead, payroll, taxes, and interest of 3.3 M. | |
| Stemtech currently holds about 399.73 K in cash with (1.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 64.0% of the company outstanding shares are owned by corporate insiders |
Stemtech Thematic Classifications
In addition to having Stemtech otc stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | ITInformation technology and IT services |
Stemtech Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.52 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Stemtech's market, we take the total number of its shares issued and multiply it by Stemtech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Stemtech Profitablity
Stemtech's profitability indicators refer to fundamental financial ratios that showcase Stemtech's ability to generate income relative to its revenue or operating costs. If, let's say, Stemtech is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Stemtech's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Stemtech's profitability requires more research than a typical breakdown of Stemtech's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (1.85) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.34) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.34. Technical Drivers
As of the 27th of January, Stemtech has the Risk Adjusted Performance of (0.12), coefficient of variation of (585.57), and Variance of 186.21. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Stemtech, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to analyze and collect data for thirteen technical drivers for Stemtech, which can be compared to its competition.Stemtech Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Stemtech middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Stemtech. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Stemtech Outstanding Bonds
Stemtech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Stemtech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Stemtech bonds can be classified according to their maturity, which is the date when Stemtech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| STLA 1711 29 JAN 27 Corp BondUS85855CAA80 | View | |
| STLA 2691 15 SEP 31 Corp BondUS85855CAB63 | View | |
| STLA 5625 12 JAN 28 Corp BondUS85855CAD20 | View | |
| STLA 6375 12 SEP 32 Corp BondUS85855CAE03 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Stemtech Predictive Daily Indicators
Stemtech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Stemtech otc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Rate Of Daily Change | 0.83 | |||
| Day Median Price | 5.0E-4 | |||
| Day Typical Price | 5.0E-4 | |||
| Price Action Indicator | (0.00005) | |||
| Period Momentum Indicator | (0.0001) | |||
| Relative Strength Index | 28.4 |
Stemtech Forecast Models
Stemtech's time-series forecasting models are one of many Stemtech's otc stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Stemtech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Stemtech Debt to Cash Allocation
Stemtech currently holds 219.47 K in liabilities. Stemtech has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Stemtech until it has trouble settling it off, either with new capital or with free cash flow. So, Stemtech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Stemtech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Stemtech to invest in growth at high rates of return. When we think about Stemtech's use of debt, we should always consider it together with cash and equity.Stemtech Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Stemtech's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Stemtech, which in turn will lower the firm's financial flexibility.Stemtech Corporate Bonds Issued
About Stemtech OTC Stock Analysis
OTC Stock analysis is the technique used by a trader or investor to examine and evaluate how Stemtech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Stemtech shares will generate the highest return on investment. We also built our otc analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual OTC such as Stemtech. By using and applying Stemtech OTC Stock analysis, traders can create a robust methodology for identifying Stemtech entry and exit points for their positions.
Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. It offers its dietary supplement products under the RCM System, stemrelease3, Stemflo MigraStem, DermaStem, DermaStem Lift, OraStem, and D-Fuze brands. Stemtech Corp operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our otc stock analysis tools, you can find out how much better you can do when adding Stemtech to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Portfolio Backtesting Now
Portfolio BacktestingAvoid under-diversification and over-optimization by backtesting your portfolios |
| All Next | Launch Module |
Other Information on Investing in Stemtech OTC Stock
Stemtech financial ratios help investors to determine whether Stemtech OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Stemtech with respect to the benefits of owning Stemtech security.